Crawley C, Ross P, Norman A, Hill A, Cunningham D
The Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, UK.
Br J Cancer. 1998 Aug;78(4):508-10. doi: 10.1038/bjc.1998.523.
The purpose of this study was to review the efficacy of a protracted venous infusion of 5-fluorouracil (PVI 5-FU)-based chemotherapy in advanced small bowel adenocarcinoma. Data on all patients with small bowel malignancy who were seen at a single institution over a 5-year period were retrieved from the gastrointestinal unit and hospital databases, and these cases were reviewed. Eight patients with advanced small bowel adenocarcinoma received PVI 5FU-based chemotherapy. The overall response rate in assessable patients was 37.5% (3/8). The median overall survival was 13 months (range 1-28), and progression-free survival was 7.8 months (range 0-15). Overall, the treatment was well tolerated and symptomatic benefit was seen. In conclusion, PVI 5-FU has activity in this disease. This should be assessed either as a single agent or as part of a combination regimen such as epirubicin/cisplatin/PVI FU (ECF) in a multicentre randomized study.
本研究旨在回顾基于5-氟尿嘧啶持续静脉输注（PVI 5-FU）的化疗在晚期小肠腺癌中的疗效。从胃肠科和医院数据库中检索了在5年期间于单一机构就诊的所有小肠恶性肿瘤患者的数据，并对这些病例进行了回顾。8例晚期小肠腺癌患者接受了基于PVI 5FU的化疗。可评估患者的总缓解率为37.5%（3/8）。中位总生存期为13个月（范围1-28个月），无进展生存期为7.8个月（范围0-15个月）。总体而言，该治疗耐受性良好且有症状改善。总之，PVI 5-FU对该疾病有活性。应在多中心随机研究中评估其作为单一药物或作为表柔比星/顺铂/PVI FU（ECF）等联合方案一部分的疗效。
